Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for RCUS

Stock NameArcus Biosciences Inc
TickerRCUS(USD) NYSE
TYPECommon Stock
CountryUSA
ISINUS03969F1093

Show aggregate RCUS holdings

News associated with RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Average Target Price from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target […] - 2025-09-09 02:29:02
US Bancorp DE Buys 12,869 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
US Bancorp DE increased its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 186.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,756 shares of the company’s stock after acquiring an additional 12,869 shares during the period. US […] - 2025-08-17 05:14:59
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Consensus Price Target from Brokerages
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price […] - 2025-08-15 02:10:59
Universal Beteiligungs und Servicegesellschaft mbH Makes New $138,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,631 shares of the company’s stock, valued at approximately $138,000. A number of other […] - 2025-08-06 04:28:49
Y Intercept Hong Kong Ltd Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
Y Intercept Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,414 shares of the company’s stock, valued at approximately $247,000. A number of […] - 2025-07-31 05:00:52
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System boosted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,700 shares of the company’s stock after purchasing an additional 5,600 shares during the quarter. Louisiana State […] - 2025-07-22 07:17:17
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong […] - 2025-06-23 03:12:48
GAMMA Investing LLC Purchases 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
GAMMA Investing LLC lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1,399.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,571 shares of the company’s stock after purchasing an additional 15,466 shares during the period. GAMMA Investing LLC’s holdings in Arcus Biosciences were […] - 2025-06-16 04:26:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% in the fourth quarter, HoldingsChannel reports. The firm owned 62,014 shares of the company’s stock after selling 7,872 shares during the quarter. UBS AM a distinct business unit […] - 2025-06-11 04:36:52
ProShare Advisors LLC Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
ProShare Advisors LLC lifted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 44.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 16,379 shares of the company’s stock after buying an additional 5,038 shares during the quarter. ProShare Advisors LLC’s holdings in Arcus Biosciences were worth $244,000 as of […] - 2025-06-01 05:46:50
Jane Street Group LLC Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS)
Jane Street Group LLC cut its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 6.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 202,500 shares of the company’s stock after selling 14,541 shares during the quarter. Jane Street Group LLC’s holdings in Arcus Biosciences were worth $3,015,000 at the […] - 2025-05-14 06:38:56
Voya Investment Management LLC Acquires 6,733 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Voya Investment Management LLC increased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 37.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,674 shares of the company’s stock after acquiring an additional 6,733 shares during the period. Voya Investment Management LLC’s holdings in Arcus Biosciences were worth $367,000 at […] - 2025-05-11 05:44:50
Arcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak Earnings
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price gapped down prior to trading on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $8.12, but opened at $7.44. Arcus Biosciences shares last traded at $7.47, with a volume of 384,839 shares trading hands. The company reported ($1.14) earnings […] - 2025-05-09 02:40:50
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,702,302 shares of the company’s stock after buying an additional 178,351 shares during the period. Dimensional Fund Advisors LP’s holdings in Arcus Biosciences were worth […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Purchases 2,521 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
MetLife Investment Management LLC boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 8.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,525 shares of the company’s stock after purchasing an additional 2,521 shares during the period. MetLife […] - 2025-05-06 05:41:07
Invesco Ltd. Raises Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
Invesco Ltd. boosted its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 203,987 shares of the company’s stock after buying an additional 35,905 shares during the quarter. Invesco Ltd.’s holdings in Arcus […] - 2025-04-28 04:54:53
Legal & General Group Plc Sells 1,837 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Legal & General Group Plc cut its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 149,207 shares of the company’s stock after selling 1,837 shares during the quarter. Legal & General Group Plc’s holdings in Arcus Biosciences were worth […] - 2025-04-25 05:10:47
KLP Kapitalforvaltning AS Makes New $207,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS)
KLP Kapitalforvaltning AS purchased a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 13,900 shares of the company’s stock, valued at approximately $207,000. Other institutional investors and hedge funds have also […] - 2025-04-08 05:44:58
Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $30.25
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-03-20 04:52:43
AlphaQuest LLC Has $110,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS)
AlphaQuest LLC reduced its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,405 shares of the company’s stock after selling 2,026 shares during the quarter. AlphaQuest LLC’s holdings […] - 2025-03-19 06:10:45
Principal Financial Group Inc. Purchases 7,906 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Principal Financial Group Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 263,517 shares of the company’s stock after buying an additional 7,906 shares during the quarter. Principal Financial Group Inc.’s holdings in Arcus Biosciences were worth $3,924,000 at the […] - 2025-03-05 06:22:48
Handelsbanken Fonder AB Purchases 2,500 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)
Handelsbanken Fonder AB grew its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,800 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Handelsbanken Fonder […] - 2025-03-03 06:59:09
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by New York State Teachers Retirement System
New York State Teachers Retirement System lowered its holdings in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 90,543 shares of the company’s stock after selling 3,708 shares during the quarter. New York State Teachers Retirement System’s holdings in Arcus Biosciences were worth $1,348,000 […] - 2025-02-24 06:25:09
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Target Price from Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong […] - 2025-02-21 04:48:43
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst Downgrade
Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday after Morgan Stanley lowered their price target on the stock from $36.00 to $25.00. Morgan Stanley currently has an overweight rating on the stock. Arcus Biosciences traded as low as $10.65 and last traded at $11.00, […] - 2025-02-19 04:30:55
R Squared Ltd Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)
R Squared Ltd bought a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 1,720 shares of the company’s stock, valued at approximately $26,000. Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Hong Kong […] - 2025-02-05 06:42:51

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc RCUS holdings

DateNumber of RCUS Shares HeldBase Market Value of RCUS SharesLocal Market Value of RCUS SharesChange in RCUS Shares HeldChange in RCUS Base ValueCurrent Price per RCUS Share HeldPrevious Price per RCUS Share Held
2025-10-16 (Thursday)11,089USD 184,077USD 184,077
2025-10-15 (Wednesday)11,089USD 187,404USD 187,404
2025-10-13 (Monday)10,879USD 181,027USD 181,027
2025-10-09 (Thursday)10,879USD 164,926USD 164,926
2025-10-07 (Tuesday)10,879USD 152,632USD 152,632
2025-10-06 (Monday)10,844USD 157,021USD 157,021
2025-10-03 (Friday)10,844USD 144,767RCUS holding decreased by -217USD 144,7670USD -217 USD 13.35 USD 13.37
2025-10-02 (Thursday)10,844RCUS holding increased by 35USD 144,984RCUS holding decreased by -721USD 144,98435USD -721 USD 13.37 USD 13.48
2025-10-01 (Wednesday)10,809USD 145,705RCUS holding decreased by -1297USD 145,7050USD -1,297 USD 13.48 USD 13.6
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RCUS by Blackrock for IE00B3VWM098

Show aggregate share trades of RCUS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-02BUY35 13.370* 10.93
2025-09-30BUY70 13.600* 10.90
2025-09-11BUY140 11.500* 10.86
2025-08-21SELL-35 10.480* 10.86 Profit of 380 on sale
2025-07-31BUY105 9.130* 10.88
2025-06-30SELL-70 8.140* 11.11 Profit of 778 on sale
2025-06-25SELL-35 8.620* 11.17 Profit of 391 on sale
2025-06-20SELL-70 8.620* 11.23 Profit of 786 on sale
2025-05-23BUY35 9.020* 11.55
2025-05-19SELL-35 8.710* 11.64 Profit of 408 on sale
2025-05-15SELL-105 8.570* 11.70 Profit of 1,228 on sale
2025-05-12SELL-35 8.800* 11.78 Profit of 412 on sale
2025-05-09SELL-35 8.280* 11.81 Profit of 413 on sale
2025-04-30SELL-35 8.750* 12.03 Profit of 421 on sale
2025-04-24SELL-70 8.410* 12.18 Profit of 852 on sale
2025-04-17SELL-35 7.880* 12.40 Profit of 434 on sale
2025-04-15SELL-105 8.010* 12.50 Profit of 1,312 on sale
2025-04-14SELL-105 7.680* 12.55 Profit of 1,318 on sale
2025-04-09SELL-140 7.940* 12.71 Profit of 1,779 on sale
2025-04-07SELL-245 7.260* 12.84 Profit of 3,145 on sale
2025-04-04SELL-350 6.870* 12.90 Profit of 4,517 on sale
2025-03-31BUY35 7.850* 13.09
2025-03-19SELL-70 9.090* 13.56 Profit of 949 on sale
2025-03-14SELL-210 9.340* 13.74 Profit of 2,886 on sale
2025-03-13SELL-70 9.540* 13.80 Profit of 966 on sale
2025-03-12SELL-1,190 9.700* 13.86 Profit of 16,492 on sale
2025-03-07SELL-70 9.580* 14.05 Profit of 983 on sale
2025-03-06SELL-105 10.020* 14.11 Profit of 1,481 on sale
2025-03-03SELL-35 10.500* 14.30 Profit of 501 on sale
2025-02-28SELL-210 10.890* 14.36 Profit of 3,016 on sale
2025-02-26SELL-35 10.140* 14.50 Profit of 508 on sale
2025-02-25SELL-105 10.240* 14.58 Profit of 1,531 on sale
2025-02-18BUY175 10.960* 15.00
2025-02-13BUY35 12.700* 15.12
2025-02-12BUY35 12.000* 15.18
2025-02-11BUY105 11.970* 15.25
2025-02-06BUY315 13.010* 15.42
2025-01-27BUY35 13.470* 15.89
2024-12-30BUY175 14.910* 16.11
2024-12-06BUY140 17.290* 15.98
2024-12-05BUY35 17.110* 15.94
2024-12-04BUY175 17.100* 15.90
2024-11-29BUY175 15.440* 15.89
2024-11-27BUY140 15.800* 15.90
2024-11-26BUY35 15.790* 15.90
2024-11-25SELL-8,268 14.560* 15.97 Profit of 132,020 on sale
2024-11-21BUY295 14.280* 16.12
2024-11-20BUY177 14.620* 16.21
2024-11-18BUY708 14.430* 16.42
2024-11-12BUY472 16.770* 16.40
2024-11-08BUY295 17.850* 16.30
2024-11-07BUY885 16.460* 16.28
2024-11-06BUY118 15.730* 16.33
2024-10-31BUY59 15.300* 16.79
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RCUS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19162,0430295,21454.9%
2025-09-1878,9090150,55452.4%
2025-09-17196,741169323,52760.8%
2025-09-1660,86267497,87562.2%
2025-09-1588,2780142,97261.7%
2025-09-12164,0670231,13871.0%
2025-09-11140,8520241,73558.3%
2025-09-10173,8020301,38657.7%
2025-09-0953,6530108,32449.5%
2025-09-08293,1703,700481,54760.9%
2025-09-05215,1660344,51062.5%
2025-09-04300,6200421,10171.4%
2025-09-03193,3100429,46545.0%
2025-09-0292,1320135,34868.1%
2025-08-29120,465158183,30165.7%
2025-08-28196,3270248,28579.1%
2025-08-2778,632375156,63050.2%
2025-08-2657,2650131,37443.6%
2025-08-2573,9950148,21449.9%
2025-08-2285,1490208,00240.9%
2025-08-2194,5900171,77655.1%
2025-08-20111,9560209,82653.4%
2025-08-19183,1940237,87577.0%
2025-08-18101,3810177,55357.1%
2025-08-15141,4060281,57450.2%
2025-08-14143,4850231,87161.9%
2025-08-13132,09799308,11742.9%
2025-08-12211,9390402,86352.6%
2025-08-11204,4730344,92059.3%
2025-08-08100,8049,754263,71338.2%
2025-08-07251,216100493,78750.9%
2025-08-06139,5620238,88358.4%
2025-08-05100,0353,000240,80241.5%
2025-08-0446,25731114,03440.6%
2025-08-0167,2250353,61519.0%
2025-07-3156,8390183,39731.0%
2025-07-3064,8220125,84651.5%
2025-07-2974,5680260,10028.7%
2025-07-28248,8510448,79355.4%
2025-07-25124,2260234,00753.1%
2025-07-2490,9774,124193,86046.9%
2025-07-2359,0150167,26735.3%
2025-07-2235,6402,661128,88427.7%
2025-07-2150,9080139,77236.4%
2025-07-1836,5670114,92731.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.